Brahmananda Makkapati, MD
Psychiatry · Des Moines, IANPI 1033157557
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 60.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $795 and has fallen 97.2% since, to $22 in 2025.
Across 168 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$626
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$208
- Teva Pharmaceuticals USA, Inc.$114
- Otsuka America Pharmaceutical, Inc.$96
- Lundbeck LLC$35
- plus $15 from 1 others
What the payments were for
- Food & beverage$2,71997%
- Education$773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 125 | $1,703 |
| Alkermes, Inc. | 19 | $626 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $208 |
| Teva Pharmaceuticals USA, Inc. | 8 | $114 |
| Otsuka America Pharmaceutical, Inc. | 6 | $96 |
| Lundbeck LLC | 2 | $35 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$438
- VRAYLAR$333
- ARISTADA INITIO$109
How this compares
$2,796 in reported general payments places this provider in the 85th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 400 | $576,654 |
| AristadaAripiprazole Lauroxil | 105 | $350,997 |
| Invega SustennaPaliperidone Palmitate | 119 | $322,503 |
| AustedoDeutetrabenazine | 40 | $284,031 |
| IngrezzaValbenazine Tosylate | 16 | $138,678 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $47,820 |
| CaplytaLumateperone Tosylate | 25 | $43,589 |
| RexultiBrexpiprazole | 27 | $39,152 |
| Clozapine | 107 | $8,491 |
| Quetiapine Fumarate | 448 | $8,236 |
| TrintellixVortioxetine Hydrobromide | 16 | $7,875 |
| Divalproex Sodium ErDivalproex Sodium | 182 | $7,159 |
| Lurasidone Hcl | 36 | $6,065 |
| Aripiprazole | 167 | $5,501 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,703 | $576,654400 claims |
| Alkermes, Inc.Aristada, Lybalvi | $626 | $398,818136 claims |
| Johnson & JohnsonInvega Sustenna | $15 | $322,503119 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $114 | $284,03140 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $208 | $43,58925 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $96 | $39,15227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Des Moines
- Manmohan SinghDes Moines$408K
- Thomas KoithanDes Moines$9K
- Leonard RichardsDes Moines$1K
- Wook KimDes Moines$1K
- Charles JennischUrbandale$949K
- Jimmy MascaroOttumwa$361K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
- Randall KavalierWest Des Moines$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.